For Boehringer, legacy drugs fund big bets in cancer, NASH

17 April 2019

At its annual press conference in Ingelheim, just outside Frankfurt, privately-held German drugmaker Boehringer Ingelheim revealed net sales of 17.5 billion euros ($19.8 billion) for 2018, down 3.3% from 18.1 billion euros the year before.

Adjusting for currency headwinds stemming from a relatively weak euro against the dollar, as well as lingering effects from 2017’s asset swap with Sanofi (Euronext: SAN), net sales grew by 4%.

Continued strong performance from legacy products in diabetes and from respiratory workhorse Spiriva (tiotropium bromide) offset foreseeable declines in net sales due to expiring patents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK